Sudan Loganathan
Stock Analyst at Stephens & Co.
(0.82)
# 3,839
Out of 4,941 analysts
32
Total ratings
28%
Success rate
-15.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Reiterates: Overweight | $30 | $10.02 | +199.40% | 4 | Jul 10, 2025 | |
| EXEL Exelixis | Upgrades: Overweight | $29 → $60 | $37.95 | +58.10% | 5 | Jun 24, 2025 | |
| DCTH Delcath Systems | Reiterates: Overweight | $25 | $10.88 | +129.78% | 3 | Jun 23, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $9.91 | +202.72% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $20.34 | +62.24% | 2 | Feb 27, 2025 | |
| ADCT ADC Therapeutics | Maintains: Overweight | $6 → $8 | $2.94 | +172.11% | 2 | Feb 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $50 | $23.62 | +111.73% | 2 | Feb 14, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $7.22 | +107.76% | 2 | Jan 22, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $60 | $39.87 | +50.49% | 2 | Jan 21, 2025 | |
| ATNM Actinium Pharmaceuticals | Reiterates: Overweight | $5 | $1.51 | +231.13% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $4 | $2.24 | +78.57% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $6.80 | +709.42% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $1.04 | +1,150.00% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $7.56 | +1,223.17% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.49 | +1,242.28% | 1 | May 14, 2024 |
Nurix Therapeutics
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $10.02
Upside: +199.40%
Exelixis
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $37.95
Upside: +58.10%
Delcath Systems
Jun 23, 2025
Reiterates: Overweight
Price Target: $25
Current: $10.88
Upside: +129.78%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $9.91
Upside: +202.72%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $20.34
Upside: +62.24%
ADC Therapeutics
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $2.94
Upside: +172.11%
IDEAYA Biosciences
Feb 14, 2025
Reiterates: Overweight
Price Target: $50
Current: $23.62
Upside: +111.73%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $7.22
Upside: +107.76%
Kymera Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $39.87
Upside: +50.49%
Actinium Pharmaceuticals
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.51
Upside: +231.13%
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $2.24
Upside: +78.57%
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $6.80
Upside: +709.42%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $1.04
Upside: +1,150.00%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $7.56
Upside: +1,223.17%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.49
Upside: +1,242.28%